Study Using IceCure's ProSense Treatment Results In 100% Tumor Reduction In Early-Stage Breast Cancer; Shares Spike Higher
Portfolio Pulse from Benzinga Newsdesk
An independent study using IceCure Medical's ProSense treatment reported a 100% tumor reduction in early-stage breast cancer patients deemed inoperable. Conducted in Italy, the study showed complete tumor size reduction at 6 and 12 months post-cryoablation. IceCure Medical Ltd. (NASDAQ:ICCM) shares spiked following the announcement. The ProSense system, which uses cryoablation technology to destroy tumors by freezing, is highlighted for its minimally invasive approach and effectiveness in treating patients who cannot undergo surgery.
February 26, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IceCure Medical's ProSense treatment demonstrated a 100% tumor reduction in early-stage breast cancer in an independent study, leading to a spike in ICCM shares.
The positive results from the independent study using IceCure's ProSense treatment for early-stage breast cancer patients deemed inoperable indicate a significant advancement in non-surgical cancer treatment. This breakthrough is likely to increase investor confidence in IceCure Medical, reflected in the spike in ICCM shares. The 100% tumor reduction rate at both 6 and 12 months post-treatment underscores the effectiveness of the ProSense system, potentially leading to wider adoption and approval in more countries, thus positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100